The path from FDA approval to sustainable revenue is fraught with pitfalls for medtech startups. While many founders assume a breakthrough product will naturally attract buyers, industry veterans warn that most failures stem not from technological shortcomings, but from a lack of market demand and commercialization strategy. This reality was underscored in a recent discussion between Ken Nelson, Partner and Founder at Nelson Jennings Ventures, and Omar Khateeb, CEO of MarketCraft, who shared hard-won insights from their roles as investors, operators, and mentors in the medtech ecosystem.

Their perspective challenges a common misconception: that FDA clearance or breakthrough innovation alone guarantees success. Instead, they emphasize that commercialization—building market pull, navigating reimbursement hurdles, and proving adoption—is where startups either thrive or falter. For founders betting on acquisitions, the warning is stark: “You can’t rely on a strategic acquirer if you haven’t first demonstrated real market traction,” Nelson and Khateeb caution. The conversation, which took place during the MedTech Innovator RADAR event, highlights how ecosystems like these sharpen industry perspectives and de-risk the journey for early-stage companies.

Why it matters: The medtech sector is a high-stakes battleground where FDA approval is just the first milestone. According to CB Insights, over 60% of medtech startups fail to achieve commercial success within five years—not because their technology fails, but because they misjudge market needs or underinvest in go-to-market strategies. This article explores the critical gaps between innovation and revenue, backed by expert insights and actionable lessons.

The Myth of “If You Build It, They Will Buy”

Medtech startups often operate under the assumption that FDA approval is the finish line. Yet, as Nelson and Khateeb point out, the real work begins after clearance. “Founders make the mistake of thinking, *’If the product works and gets approved, the sales will follow,’*” Khateeb explains. “But the hard part—the part that drives valuation—is creating market demand.”

This disconnect is rooted in a fundamental misunderstanding of how medtech commercialization works. Unlike consumer products, medical devices and diagnostics require proof of adoption—not just clinical efficacy—to attract buyers. Investors and acquirers demand evidence that a product will generate revenue, not just fill a lab. Without this, even the most innovative solutions can languish in development limbo.

Key statistic: A Deloitte 2025 report found that 72% of medtech startups with FDA-cleared products fail to secure Series B funding—primarily because they lack a clear commercialization roadmap. This gap between innovation and execution is where Nelson Jennings Ventures and MarketCraft focus their mentorship.

Where Startups Go Wrong: The Acquisition Trap

A common pitfall is the “acquisition as a backup plan” mentality. Many founders assume that once their product is FDA-approved, a strategic buyer will inevitably step in. Nelson warns against this approach: “You can’t bank on an acquisition without proving market pull first. Valuation is driven by revenue, not potential.“

Khateeb echoes this, citing examples where startups with promising technology failed to secure acquisitions because they couldn’t demonstrate real-world adoption. “Reimbursement pathways, payer contracts, and clinician buy-in aren’t optional—they’re table stakes,” he says. Without these, even the most innovative devices risk becoming “shelfware.”

Why this matters: The medtech acquisition landscape is shifting. According to PwC’s 2026 Health Industries Report, only 12% of medtech acquisitions in the past year were for pre-revenue companies. The rest targeted startups with proven revenue streams and clinical adoption data.

The Three Pillars of Medtech Success: Regulation, Reimbursement, and Commercialization

Nelson and Khateeb identify three critical pillars that separate successful medtech startups from those that fail:

• Regulatory agility: Navigating FDA pathways is complex, but startups must also anticipate EU MDR and other global regulations. “A product that clears the FDA but fails in Europe is still a failure,” Nelson notes.
• Reimbursement strategy: Without payer coverage, even life-saving devices may not reach patients. Khateeb advises startups to engage with CMS and private insurers before launch to secure codes and contracts.
• Commercialization execution: This is where most startups stumble. “You need a go-to-market plan that aligns with clinician workflows, hospital procurement cycles, and distributor incentives,” Khateeb says.

Their advice to founders: Treat commercialization as a core competency, not an afterthought. This means hiring sales leaders early, building relationships with KOLs (key opinion leaders), and piloting in controlled markets before scaling.

Balancing Conviction and Coachability: The Founder’s Dilemma

Successful medtech founders share two traits: unshakable conviction in their vision and humility in execution. Nelson describes this as “knowing your product’s value while staying open to market feedback.” Khateeb adds: “The best founders are coachable—they listen to investors, clinicians, and regulators, but they don’t lose sight of their north star.”

This balance is critical because medtech is a team sport. Startups rarely succeed in isolation; they thrive by leveraging ecosystems like MedTech Innovator, Adva360, and MedTech Innovator’s RADAR program. These platforms provide access to mentors, investors, and peer learning—resources that can accelerate growth and mitigate risk.

Actionable Lessons for Founders, Investors, and Advisors

For those building, investing in, or advising medtech companies, Nelson and Khateeb offer these key takeaways:

• Start with market demand: Validate your product’s adoption potential before scaling development. “If no one is willing to pay for it, no one will buy it,” Khateeb warns.
• Prioritize reimbursement early: Engage payers and regulators as part of your product development cycle.
• Avoid the acquisition fantasy: Focus on revenue growth, not just FDA clearance.
• Leverage ecosystems: Programs like MedTech Innovator RADAR provide mentorship and networking critical to survival.
• Hire for commercialization: Technical founders often lack sales and operations expertise—fill these gaps early.

What’s Next? The Future of Medtech Commercialization

The medtech landscape is evolving, with trends like AI-driven diagnostics and digital therapeutics reshaping the sector. Nelson and Khateeb predict that startups embracing data-driven commercialization—using real-world evidence to guide go-to-market strategies—will outperform competitors relying on intuition alone.

For founders, the message is clear: Success in medtech is no longer about the technology. It’s about the market. Those who master commercialization early will not only survive but thrive in an increasingly competitive space.

What’s your experience with medtech commercialization? Share your insights in the comments below.

For more expert analysis, follow Nelson Jennings Ventures and MarketCraft on LinkedIn.